Survival Extended With Pembrolizumab/Chemotherapy in Esophageal Cancer
Ken Kato, MD discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.
Ken Kato, MD, of the National Cancer Center Hospital in Tokyo, Japan discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.
The results, which were presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020, evaluated the efficacy of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment of patients with advanced esophageal cancer. The combination demonstrated improvements were seen in both progression-free survival and overall survival.
According to Kato, the safety profile was manageable. The confirmed overall response rate was 45% for the combination and 29.3% for the chemotherapy alone. The rate adverse effects for the combination was slightly higher for the combination, 72% and 68% for chemotherapy alone. The rate of discontinuation from drug-related adverse events was 19% for the combination and 12% for the chemotherapy alone.
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Axi-Cel Efficacy in R/R Indolent Non-Hodgkin Lymphoma Sustained at 5 Years
December 10th 2024“These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or refractory indolent non-Hodgkin lymphoma, with curative potential in patients with follicular lymphoma,” said Sattva S. Neelapu, MD.
Read More
Novel BTK Degrader BGB-16673 Shows Activity in WM and CLL/SLL
December 10th 2024The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.
Read More
